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Abstract
Both endothelial and immune dysfunction contribute to the high mortality rate in human sepsis, but the underlying
mechanisms are unclear. In response to infection, interferon-c activates indoleamine 2,3-dioxygenase (IDO) which
metabolizes the essential amino acid tryptophan to the toxic metabolite kynurenine. IDO can be expressed in endothelial
cells, hepatocytes and mononuclear leukocytes, all of which contribute to sepsis pathophysiology. Increased IDO activity
(measured by the kynurenine to tryptophan [KT] ratio in plasma) causes T-cell apoptosis, vasodilation and nitric oxide
synthase inhibition. We hypothesized that IDO activity in sepsis would be related to plasma interferon-c, interleukin-10, T
cell lymphopenia and impairment of microvascular reactivity, a measure of endothelial nitric oxide bioavailability. In an
observational cohort study of 80 sepsis patients (50 severe and 30 non-severe) and 40 hospital controls, we determined the
relationship between IDO activity (plasma KT ratio) and selected plasma cytokines, sepsis severity, nitric oxide-dependent
microvascular reactivity and lymphocyte subsets in sepsis. Plasma amino acids were measured by high performance liquid
chromatography and microvascular reactivity by peripheral arterial tonometry. The plasma KT ratio was increased in sepsis
(median 141 [IQR 64–235]) compared to controls (36 [28–52]); p,0.0001), and correlated with plasma interferon-c and
interleukin-10, and inversely with total lymphocyte count, CD8+ and CD4+ T-lymphocytes, systolic blood pressure and
microvascular reactivity. In response to treatment of severe sepsis, the median KT ratio decreased from 162 [IQR 100–286]
on day 0 to 89 [65–139] by day 7; p = 0.0006) and this decrease in KT ratio correlated with a decrease in the Sequential
Organ Failure Assessment score (p,0.0001). IDO-mediated tryptophan catabolism is associated with dysregulated immune
responses and impaired microvascular reactivity in sepsis and may link these two fundamental processes in sepsis
pathophysiology.
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Introduction
Sepsis is a systemic inflammatory response to infection [1].
Despite advances in its management, severe sepsis still has a
mortality rate of 30–50% [2,3,4]. Both immune and endothelial
dysfunction are thought to contribute to the high mortality rate in
sepsis [5,6], however the underlying mechanisms are not
completely understood.
Tryptophan is an essential amino acid that is central to cellular
respiration [7] and neurotransmission [8], and is a key immune
mediator. During inflammation, tryptophan is metabolised by
indoleamine 2,3-dioxygenase (IDO) to the toxic metabolite
kynurenine. IDO activity is measured by the ratio of kynurenine
to tryptophan (the KT ratio). Endothelial cells, monocytes, renal
tubular epithelial cells and hepatocytes express IDO in response to
interferon-c [9,10,11,12,13] and IL10 stabilises IDO expression
[14].
IDO activity regulates a number of immune responses.
Increased IDO activity inhibits T cell function [15] and
proliferation [14,16,17] and contributes to T cell apoptosis [18].
Furthermore, elevated IDO activity inhibits nitric oxide synthase
and vice versa [19,20,21]. Recent isotope studies have shown that
systemic NO production is either reduced or unchanged in human
sepsis compared with healthy controls [22,23,24].
In addition to regulating the immune response, IDO activity may
also regulate endothelial function. Kynurenine, a metabolite of
IDO, has recently been described as an endogenous vasorelaxing
factor [9]. Increased IDO activity would therefore be expected to
directly decrease systemic vascular resistance. Additionally, as IDO
inhibits NOS, IDO may indirectly affect endothelial function by
impairing NO-dependent microvascular reactivity. NO is essential
for normal endothelial function and NO-dependent microvascular
reactivity has been previously shown to be impaired in patients with
sepsis, in proportion to disease severity [25,26]. Finally, plasma
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kynurenine concentrations have been associated with markers of
endothelial dysfunction in patients with end-stage renal disease [27].
IDO activity correlates with disease severity in patients with
chronic inflammatory diseases such as human immunodeficiency
virus [28], systemic lupus erythematosus [29] and malignancy
[30], but little is known about IDO activity in acute inflammatory
states. A raised KT ratio has recently been reported in patients
with bacteremia [31].
We investigated the relationship between the KT ratio and
disease severity in sepsis. We hypothesised that the KT ratio would
be related to IFN-c and IL10 concentrations, and inversely related
to both T cell lymphopenia and microvascular reactivity, a
measure of endothelial NO bioavailability.
Methods
Participants
We evaluated patients with sepsis and hospital controls who were
part of a previously reported study of endothelial function in sepsis
[25]. Sepsis patients had suspected or proven infection and the
presence of two or more criteria for the systemic inflammatory
response syndrome (SIRS) within the last 4 hours [1]. Severe sepsis
patients had organ dysfunction or shock at the time of enrolment
according to the American College of Chest Physicians/Society of
Critical Care Medicine criteria [1,32]. Sepsis severity was estimated
using the Acute Physiology and Chronic Health Evaluation
(APACHE) II score from the first 24 hours of admission and daily
modified Sequential Organ Failure Assessment (SOFA) score [33].
Patients were enrolled within 24 hours of ICU admission or within
36 hours of ward admission. Control subjects were recruited from
hospital patients who had not met SIRS criteria within the last 30
days and who had no clinical or laboratory evidence of inflammation
or infection. Written informed consent was obtained from all
participants or next of kin. All sepsis patients had undergone
resuscitation and were haemodynamically stable at the time of study
enrolment. The study was approved by the Human Research Ethics
Committee of Menzies School of Health Research and the
Department of Health and Community Services.
Blood collection and lymphocyte counts
Venous blood was collected in lithium heparin tubes at
enrolment, day 2–4, and day 7 until discharge from the hospital
or death. Whole blood differential white cell counts were
measured by Coulter Counter. Lymphopenia was defined as an
absolute lymphocyte count less than 1.26103/mL [34]. Plasma was
separated and stored at 280uC.
Lymphocytes were analysed in more detail in a subset of
patients from whom samples were processed within 30 minutes of
collection, matched for age and gender. Peripheral blood
mononuclear cells were separated using Ficoll-PaqueTM Plus
(GE Healthcare Biosciences, Uppsala, Sweden) and cryopreserved
in fetal calf serum and dimethyl sulfoxide. Cells were thawed and
stained with appropriate antibodies and analysed on a FACSCa-
libur flow cytometer (Becton Dickinson Immunocytometry
Systems, MA, USA). Antibodies were sourced from Biolegend,
California, USA (CD3, CD16 and CD56) or BD Biosciences
Pharmingen, California, USA (CD4 and CD8). Results were
analysed using Flow Jo software (Tree Star, Oregon, USA). T cells
were defined as CD3+ lymphocytes and natural killer cells were
defined as CD32CD16+CD56+ lymphocytes.
Tryptophan and kynurenine measurements
Plasma tryptophan and kynurenine concentrations were
measured by High Pressure Liquid Chromatography (HPLC;
Shimadzu, Kyoto, Japan) with UV (250 nm) and fluorescence
(excitation 250 nm, emission 395 nm) detection, using a method
modified from van Wandelen and Cohen [35]. The kynurenine to
tryptophan (KT) ratio was calculated by dividing the kynurenine
concentration (mmol/L) by the tryptophan concentration (mmol/L)
and multiplying the quotient by 1000 [28,36,37].
Plasma cytokine measurements
Concentrations of plasma IFN-c, IL6 and IL10 were deter-
mined using a cytometric bead array (Human Th1/Th2 Cytokine
Kit II, BD Biosciences Pharmingen, CA, USA) and a FACSCa-
libur flow cytometer (Becton Dickinson Immunocytometry
Systems, MA, USA). Results were analysed using FCAP array
version 1.0.1 (Soft Flow Hungary for Becton Dickinson Biosci-
ences). The lower limits of detection (LLD) of the assay were
2.5 pg/mL for IFN-c and 10 pg/mL for IL6 and IL10. Values
below the LLD were assigned a value halfway between zero and
the LLD for statistical analysis. Cytokines were only measured if
plasma had been frozen within 2 hours of collection.
Measurement of endothelial function
Sepsis patients underwent serial bedside reactive hyperemia
peripheral arterial tonometry (RH-PAT) measurements at enrol-
ment, day 2–4, and day 7 [25]. Control patients had the same
assessment at a single time point. RH-PAT (Itamar Medical,
Caesarea, Israel) is a non-invasive operator-independent method
of assessing endothelial function. Endothelial function is defined by
the ability of blood vessels to vasodilate in response to an ischemic
stress, which invasive studies have demonstrated to be dependent
on endothelial cell NO production [38]. RH-PAT is at least 50%
NO-dependent [39]. RH-PAT uses finger probes to measure
digital pulse wave amplitude detected by a pressure transducer
[40], and has been validated against the more operator-dependent
flow-mediated dilatation method [41] and with endothelial
function in other vascular beds [42].
Statistical methods
Predefined groups for analysis were severe sepsis, non-severe
sepsis (meaning sepsis without evidence of organ dysfunction or
shock at enrolment), and hospital controls. Continuous parametric
variables were compared using Student’s t-test or ANOVA while
continuous non-parametric variables were compared using Mann-
Whitney, Kruskal-Wallis or Wilcoxon tests as appropriate.
Correlations were examined using Pearson’s or Spearman’s tests
for parametric and non-parametric data respectively. As SOFA
score was highly right-skewed and no transformation gave a
normal distribution, Kendall’s tau coefficient for partial correla-
tion was used for multivariate analysis involving SOFA [43].
Linear mixed-effects models were used to examine longitudinal
correlations. A 2-sided p-value of ,0.05 was considered
significant. Analyses were performed using Stata version 10.0
(Stata Corp TX, USA) and Prism version 5.01 (GraphPad
Software, CA, USA).
Results
Patients
The study included 50 patients with severe sepsis, 30 with non-
severe sepsis and 40 hospital controls. The three groups did not
differ significantly in age or gender (Table 1). Ninety percent of
severe sepsis patients and all non-severe sepsis patients were either
orally or enterally fed at the time of enrolment; none were
receiving parenteral nutrition.
KT Ratio in Sepsis
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21185
IDO activity and sepsis severity
Plasma tryptophan concentrations were significantly reduced in
patients with sepsis (p,0.0001, Figure 1 and Table 2). In all
sepsis patients, plasma tryptophan was inversely related to SOFA
score (r =20.45, p,0.0001). There was no difference in the
baseline plasma tryptophan concentrations among severe sepsis
patients who were orally fed (n = 29), enterally fed (n = 16) or who
were nil by mouth (n= 5).
Conversely, plasma kynurenine concentrations were elevated in
sepsis patients compared to hospital controls (p,0.0001, Figure 1
and Table 2). In all sepsis patients, plasma kynurenine correlated
with SOFA score (r = 0.34, p= 0.005). As kynurenine is renally
excreted and accumulates in renal failure [44,45], kynurenine
concentrations were tested for relationships with renal impair-
ment. Kynurenine concentrations were significantly higher in
patients requiring continuous renal replacement therapy (CRRT)
(median 4.5 mmol [IQR 4–5.3]) than in patients not receiving
CRRT (2.8 mmol [2.1–4.4]; p = 0.03). In all sepsis patients,
kynurenine concentration correlated with plasma creatinine
(r = 0.41, p= 0.0002). Nevertheless, the association between
plasma kynurenine concentration and SOFA score remained
significant even after controlling for creatinine (ktau = 0.24,
p,0.01).
IDO activity was significantly increased in sepsis patients
(median KT ratio 141 [IQR 64–235]) compared to controls (36
[28–52]) (p,0.0001) and in severe sepsis compared to non-severe
sepsis (p = 0.0006, Table 2). The baseline KT ratio correlated
with APACHE II (rs = 0.51, p,0.0001) and total SOFA scores
(rs = 0.54, p,0.0001) in sepsis patients. The KT ratio positively
correlated with the hepatic (rs = 0.28, p = 0.01), renal (rs = 0.53,
p,0.0001), cardiovascular (rs = 0.42, p,0.0001) and respiratory
(rs = 0.36, p = 0.0009) components of the SOFA score but not the
coagulation component (rs = 0.13, p =ns).
Of the 80 sepsis patients, 6 died by day 28 of the study. The
baseline KT ratio in patients who died (median 270 [IQR 102–
431] was not statistically significantly different to those who
survived (138 [63–232]; p= 0.2).
In longitudinal analysis of severe sepsis, the KT ratio
significantly decreased between day 0 (median 162 [IQR 100–
286]) and day 7 (89 [65–139]), p = 0.0006); Figure 1D. Among all
sepsis patients, decrease in KT ratio correlated with decrease in
SOFA score over time (p,0.0001).
IDO activity and plasma cytokines
Plasma IFN-c, IL6 and IL10 were all significantly increased in
patients with sepsis (Table 2). Plasma concentrations of IL1, IL2,
IL4 and tumour necrosis factor-a were not significantly increased
in this cohort and were not analysed further. Both IL6 and IL10
positively correlated with SOFA score (rs = 0.55, p,0.0001 and
rs = 0.55, p,0.0001 respectively) but there was no association
between IFN-c and SOFA score.
In sepsis patients, the KT ratio correlated with plasma IFN-c
(rs = 0.44, p= 0.0002), IL6 (rs = 0.49, p,0.0001) and IL10
(rs = 0.62, p,0.0001). The associations between KT ratio and IL6
and IL10 remained significant after controlling for SOFA score
(ktau=0.30, p,0.003 and ktau= 0.45, p,0.0001 respectively).
Table 1. Baseline clinical characteristics of participants.
Severe sepsis Non-severe sepsis Controls p value*
Subjects (n) 50 30 40
Age{ 52 (48–57) 50 (46–55) 48 (44–52) NS
Male – n (%) 29 (58%) 20 (67%) 27 (68%) NS
Diabetic – n (%) 16 (32%) 7 (23%) 13 (33%) NS
Mean Arterial Pressure{ 74 (70–82)
n = 50
88 (77–104)
n = 30
80 (73–93)
n = 37
0.001
Systolic Blood Pressure{ 113 (105–132)
n = 49
123 (110–140)
n = 24
115 (110–128)
n = 37
NS
Diastolic Blood Pressure{ 60 (54–68)
n = 49
70 (60–90)
n = 24
60 (60–75)
n = 37
0.002
APACHE II{ 19 (15–23) 7 (5–12) ,0.0001
SOFA score (day 0){ 6 (3–9) 1 (0–2) ,0.0001
RH-PAT index{ 1.59 (1.45–1.73)
n = 45
1.86 (1.67–2.05)
n = 26
2.04 (1.91–2.18)
n = 36
,0.0001
Causative Organism – n (%) NS
None Cultured 23 (46%) 20 (67%)
Gram Positive Bacterium 14 (28%) 4 (13%)
Gram Negative Bacterium 13 (26%) 6 (20%)
Nutrition – n (%)
Oral feeding 29 (58%) 29 (97%)
Enteral feeding 16 (32%) 1 (3%)
Nil By Mouth 5 (10%)
*For difference between all 3 groups by one way analysis of variance.
{Mean (95% confidence interval).
{Median (interquartile range).
doi:10.1371/journal.pone.0021185.t001
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In a univariate mixed effects model, the decrease in KT ratio
over time correlated with the decrease in IL6 (p,0.0001) and IL10
(p,0.0001) between day 0 and day 7. In a multivariate model,
these relationships remained significant after controlling for
change in SOFA score (IL6 p= 0.009; IL10 p= 0.02).
IDO activity and lymphocyte counts
Sepsis patients had increased white blood cell counts
(p,0.0001) primarily due to increased circulating neutrophils
(p,0.05; Table 2), which proliferate in response to bacterial
infections [46]. Conversely, sepsis patients had significantly lower
total lymphocyte counts compared with hospital controls
(p,0.0001, Table 2). In all sepsis patients the baseline KT ratio
was weakly associated with absolute lymphocyte count (rp = 0.26,
p = 0.02). In a linear mixed effects model, absolute lymphocyte
count increased as the KT ratio decreased over time (p = 0.001).
This relationship persisted after controlling for SOFA score
(p = 0.008). When all subjects were grouped according to
lymphopenia, lymphopenic patients (n = 63) had a median KT
ratio of 128 [IQR 63–236], compared with 59 [33–86] in non-
lymphopenic patients (n = 57) (p,0.0001).
As IDO activity contributes to T cell apoptosis [18], we
examined the relationship between KT ratio and lymphocyte
subsets. Peripheral blood mononuclear cells were analysed from 23
of the 80 sepsis patients whose blood had been processed within
30 minutes of collection. This subset of patients was representative
of the cohort in terms of age, gender distribution, total lymphocyte
count and KT ratio. In this subset of patients, the KT ratio
negatively correlated with absolute numbers of lymphocytes
(rp =20.54, p = 0.007), T cells (rp =20.53, p = 0.01), CD4+ T
cells (rp =20.50, p= 0.01), CD8+ T cells (rp =20.49, p= 0.02)
and natural killer cells (rp =20.46, p = 0.03) (Table 2).
Figure 1. Plasma assessment of tryptophan catabolism. The concentration of plasma tryptophan (Fig. 1A), kynurenine (Fig. 1B) and the KT
ratio (Fig. 1C) in 50 severe sepsis patients, 30 non-severe sepsis patients and 40 hospital controls. Fig. 1D shows the KT ratio in severe sepsis patients
on admission (n = 50), day 2 (n = 34) and day 7 (n = 16). The KT ratio is determined by dividing the plasma kynurenine concentration (mmol/L) by the
plasma tryptophan concentration (mmol/L) and multiplying the quotient by 1000. Horizontal lines represent median values for the group. P value
analysis in Figs. 1A–C used a Mann Whitney test, and in Fig. 1D, a paired Wilcoxon test.
doi:10.1371/journal.pone.0021185.g001
KT Ratio in Sepsis
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21185
IDO activity and endothelial function
In sepsis, the KT ratio at baseline correlated inversely with NO-
dependent microvascular reactivity (rs =20.45, p = 0.001) even
after controlling for disease severity (using SOFA score; p = 0.001).
In a multivariate mixed effects model controlling for SOFA score,
improvement in KT ratio between day 0 and day 7 correlated with
improvement in microvascular reactivity (p = 0.001). In all sepsis
patients, there was an inverse association between the baseline KT
ratio and mean arterial pressure (rs =20.29, p = 0.009) and
diastolic blood pressure (rs =20.29, p = 0.01) but no association
with systolic blood pressure.
Discussion
IDO activity is increased in sepsis, in proportion to disease
severity. IDO-mediated tryptophan catabolism is associated with
dysregulated immune responses and impaired microvascular
reactivity in sepsis. IFN-c and IL10 are associated with, and
may contribute to, increased IDO activity in sepsis. The
independent inverse longitudinal association with total lymphocyte
counts suggests a potential role in sepsis-associated lymphopenia.
Similarly, the independent inverse association between the KT
ratio and microvascular reactivity suggests that IDO activity may
also contribute to impaired endothelial function in sepsis. Based on
these associations we propose a model of interpretation outlined in
Figure 2.
Increased expression of IFN-c [47], IL6 [48,49] and IL10 [14]
have each been associated with increased tryptophan catabolism
by IDO in other disease states. In sepsis patients in our study, IFN-
c concentration correlated with the KT ratio only at baseline,
whereas IL6 and IL10 correlated with the KT ratio both at
baseline and longitudinally. Our findings agree with the in vitro
literature, where IFN-c induces IDO [10,47]. Although under
certain conditions, IL-10 has been reported to suppress IDO
activity [50], our findings support the majority of in vitro studies
which have shown that IL-10 induces or stabilises IDO
[14,51,52,53]. The high IFN-c associated with early sepsis [54]
may lead to increased IDO activity while high IL10 may sustain or
potentially enhance IDO activity [53] throughout the course of the
disease. The role of IL6 in IDO expression is unclear. Orabona et
al. suggest that IL6 inhibits IDO activity by increasing murine
dendritic cell SOCS3 expression, which drives IDO breakdown
[55]. On the other hand, a low tryptophan environment created
by IDO activity stabilises IL6 mRNA and increases IL6 responses
[56]. Given the conflicting evidence in these and other studies
regarding IL6 and IDO, we investigated the relationship between
the KT ratio and IL6 in sepsis patients. The strong positive
correlation between plasma KT ratio and IL6 concentration
is consistent with findings in murine models of sepsis where
IDO2/2 mice or mice treated with IDO inhibitors have lower
plasma IL6 concentrations [57,58].
We report that the high KT ratio in sepsis is associated with a
decreased lymphocyte count, independent of disease severity, a
Table 2. Immunological characteristics of participants (median and interquartile range).
Severe sepsis Non-severe sepsis Combined sepsis Controls
Sepsis vs
Control*
n 50 30 80 40
Plasma tryptophan mmol/L 21 (13–29) 31 (23–37) 24 (14–35) 49 (40–55) ,0.0001
Plasma kynurenine mmol/L 3.5 (2.4–5.2) 2.3 (1.9–3.9) 3.1 (2.1–4.7) 1.9 (1.5–2.3) ,0.0001
KT ratio 162 (100–286) 82 (55–159) 141 (64–235) 36 (28–52) ,0.0001
Plasma IFN-c pg/mL 8 (1.3–20.1) n = 38 27 (3–84) n = 29 9 (3–48) n = 67 1.3 (1.3–7) n = 37 ,0.0001
Plasma IL6 pg/mL 380 (121–979) n = 38 136 (44–320) n = 29 222 (75–596) n = 67 5 (5-5) n = 37 ,0.0001
Plasma IL10 pg/mL 23 (13–64) n = 38 5 (5–25) n = 29 16 (5–41) n = 67 5 (5 - 5) n = 37 ,0.0001
Neutrophils6103/mL 13.5 (8.7–20.4) n = 49 14.1 (9.2–16.3) 14 (8.8–16.6) n = 79 5.1 (3.2–6.5) n = 20 0.049
Lymphocytes x6103/mL 0.9 (0.5–1.2) n = 49 1.0 (0.7–1.3) 0.9 (0.5–1.2) n = 79 2.1 (1.2–2.2) n = 20 ,0.0001
Lymphocyte subsets{ n=11 n=12 n=23 n=4
T cells6103/mL 0.65 (0.34–1.8) 0.67 (0.34–1.0) 0.65 (0.34–1.1) 1.49 (1.0–1.7) NS
CD4+ T cells6103/mL 0.35 (0.17–0.85) 0.35 (0.17–0.59) 0.35 (0.18–0.67) 0.89 (0.52–1.2) NS
CD8+ T cells6103/mL 0.18 (0.07–0.72) 0.16 (0.10–0.33) 0.18 (0.1–0.34) 0.46 (0.31–0.61) NS
NK cells6103/mL 0.07 (0.03–0.12) 0.06 (0.03–0.17) 0.06 (0.03–0.11) 0.08 (0.04–0.20) NS
*p values, all sepsis vs controls, Mann Whitney test.
{Performed in a subset of patients representative of the entire cohort, as described in methods and results. Severe sepsis n = 11, non-severe sepsis n = 12, control n = 4.
doi:10.1371/journal.pone.0021185.t002
Figure 2. Proposed model of tryptophan catabolism in sepsis.
IDO= Indoleamine 2,3-dioxygenase, IL6 = interleukin-6, IL10 = interleu-
kin-10, IFN-c= interferon gamma and NO=nitric oxide.
doi:10.1371/journal.pone.0021185.g002
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finding similar to that found in patients with trauma [37], human
immunodeficiency virus [28] and cancer [59]. Previous studies in
sepsis have associated lymphopenia with disease severity [60],
duration of ICU stay [60] and mortality [61] and prevention of
lymphocyte apoptosis improves survival in animal models of sepsis
[62,63,64,65]. T cells co-cultured with IDO-producing cells have
reduced proliferation and increased death [66,67]. Both high
kynurenine concentrations and low tryptophan concentrations
appear to contribute to T cell death. In vivo, kynurenine treatment
in mice depletes overall thymocyte counts and, in vitro, thymocytes
die of apoptosis when cultured in media with kynurenines [18].
Furthermore, T cells cultured in low tryptophan media have
reduced proliferation and increased apoptosis via activated GCN2
kinase [68,69]. These in vitro studies suggest a potential mechanism
through which increased IDO activity may contribute to
lymphopenia and its deleterious consequences in sepsis.
IDO activity regulates vascular tone in sepsis. In this study IDO
activity in sepsis patients correlated with diastolic blood pressure
but not systolic blood pressure. This is consistent with the recent
finding that kynurenine is a vascular relaxation factor [9]. Another
important regulator of endothelial function in sepsis is NO. There
is significant cross-talk between IDO and NOS, with IDO activity
inhibiting both expression and activity of NOS [19,20,21] and vice
versa. We found the KT ratio in sepsis is inversely associated with
microvascular reactivity as measured by RH-PAT, which is at least
50% dependent on endothelial NO production [70]. Increased
IDO activity in sepsis may regulate vascular tone directly, via the
vasorelaxing effects of kynurenine, and indirectly, by impairing
NO-dependent microvascular reactivity. Increased plasma kyn-
urenine concentrations may further impede endothelial function in
sepsis by mediating adhesion of monocytes and neutrophils to the
vascular endothelium [71].
A limitation of this study is that we did not directly measure
IDO expression. However, the KT ratio is an established measure
of systemic IDO activity [28,72] with tissue IDO expression and
activity directly correlated with plasma KT ratio in multiple
human disease states, including celiac disease [73], hepatitis C [11]
and pre-eclampsia [74]. There are several possible sources of IDO
activity in sepsis patients including the endothelium, kidney, liver,
lungs and leukocytes [9,10,11,12,13,53], although a recent study
was unable to detect spontaneous IDO expression in PBMC from
sepsis patients [75]. Importantly, the effects of the high KT ratio in
sepsis on immune function and endothelial function would be the
same whether the high KT ratio was the result of increased IDO
activity alone or in combination with decreased feeding and
impaired renal excretion of kynurenine. Furthermore, it is unlikely
that nutritional deficiency and renal impairment accounted for the
differences we found, because controlling for these factors made no
difference to our results.
In our study the KT ratio was not significantly associated with
mortality. Consistent with the previously reported low mortality
from severe sepsis in our ICU [32,76], there were few deaths in
our study. This suggests that our study was under-powered to
examine the relationship between IDO activity and mortality.
However, in a study with higher numbers of deaths, Hattunen and
colleagues found a clear association between plasma KT ratio and
risk of death in sepsis [31].
The generation of a low tryptophan environment may be a
maladaptive host response to infection. While growth of some
bacterial species is inhibited by low tryptophan [77], most can
synthesize tryptophan [78] and others have specialized tryptophan
transport systems [79]. In murine models of sepsis, IDO2/2 mice
have significantly increased survival compared to wild type mice
[58] and treatment of wild-type mice with IDO inhibitors such as
1-methyl-tryptophan [58] or ethyl pyruvate also significantly
increase survival [57]. The KT ratio is significantly higher in
bacteremic patients with a fatal outcome [31] and we and others
have demonstrated that the KT ratio is associated with disease
severity in sepsis [31,75,80]. Together, this evidence supports the
hypothesis that increased IDO activity is a deleterious host
response in human sepsis. IDO inhibitors are being considered as
potential adjunctive cancer treatments [81] and these treatments
may also have therapeutic potential in sepsis.
Conclusion
IDO activity is elevated in sepsis and associated with disease
severity, T cell lymphopenia and microvascular dysfunction.
Because excessive IDO activity is associated with both immune
and endothelial dysfunction, increased tryptophan catabolism may
link these two key aspects of sepsis pathophysiology. Modulation of
IDO activity warrants investigation as a therapeutic strategy in
sepsis.
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